📰 Priority Review News
Page 84 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
December 1, 2022
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer,...
December 1, 2022
PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic
December 1, 2022
FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ --
December 1, 2022
01.12.2022 - Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) - Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of ... Seite 1
December 1, 2022
Primary Vitreoretinal Lymphoma New Drug Application for ADX-2191 Expected to be Submitted as Soon as the End of 2022 Company Intends to Request Priority Review Designation ... | December 1, 2022
November 30, 2022
Week. the company believes that being together in person would enhance their ability to deliver on strategic priorities. the new policy will take effect in february. snaps just the latest tech company to try and bring workers back to the office. some good news. there may be hope in the fight against outsider. a drug has shown promise in showing the progression of the disease. the new england journal of medicine showed positive results. the drug is associated with some serious adverse effects a...
November 30, 2022
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...
November 30, 2022
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) said the FDA has accepted for Priority Review the supplemental Biologics License Application for Evkeeza as an adjunct to other lipid-lowering
November 30, 2022
The FDA has accepted for Priority Review the sBLA for evinacumab-dgnb to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia.
November 30, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis...